Health Care Segregation, Physician Recommendation, and Racial Disparities in<i>BRCA1/2</i>Testing Among Women With Breast Cancer
Anne Marie McCarthy(Massachusetts General Hospital), Katrina Armstrong(Columbia University), Judy A. Shea(University of Pennsylvania), U. Nkiru Motanya(Harvard University), Susan M. Domchek(University City Science Center), Peter W. Groeneveld(Harvard University), Mirar N. Bristol(Harvard University), Younji Kim(Harvard University)
Cited by 181
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981